Ranbaxy Laboratories

• 

  Ex-Ranbaxy Promoter Malvinder Singh Arrested By Enforcement Directorate

  Pharmaceutical giant Ranbaxy Laboratories' ex-promoter Malvinder Singh has been arrested by the Enforcement Directorate in a money laundering case.

• 

  Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Arrested In Fraud Case

  Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.

• 

  Ex-Ranbaxy Promoter Fined Nearly 18 Crore Over Court Disobedience

  The Delhi High Court Wednesday directed former Ranbaxy Laboratories Ltd promoter Malvinder Singh to deposit with it 3.5 million Singapore dollars, which he obtained by selling his shares in a company in violation of court's direction.

• 

  Fortis Healthcare Co-Owner Restrained From Selling Properties Over Loan Default

  The Delhi Debts Recovery Tribunal (DRT) has restrained former CEO of Ranbaxy Laboratories and the co-owner of Fortis Healthcare, Malvinder Mohan Singh, from selling a posh property in Lutyen's Delhi and some other assets in a bank loan default case.

• 

  Sun Pharmaceutical Wins US Approval to Buy Ranbaxy

  India's Sun Pharmaceutical Industries Ltd has won US approval to buy Ranbaxy Laboratories Ltd on condition that it sell its interest in a generic antibacterial medicine, the US Federal Trade Commission (FTC) said on Friday.

• India Caps Prices of 108 More Medicines; Drugmakers to Take Hit

  India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

• Andhra Pradesh High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover

  The Andhra Pradesh High Court on Saturday lifted a temporary stay it imposed on generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion takeover of Ranbaxy Laboratories Ltd, a lawyer involved in the case said, paving the way for both companies to complete the deal.

• Unease grows among US doctors over quality of Indian medicines

  Some US doctors are becoming concerned about the quality of generic drugs supplied by Indian manufacturers following a flurry of recalls and import bans by the Food and Drug Administration (FDA).

• Drugs sold by company in the Indian market are safe: Ranbaxy

  Ranbaxy Laboratories today insisted drugs sold by it in the Indian market are safe and effective and the company complies with country's regulations, even as the Supreme Court issued a notice to it.

• Flies in Ranbaxy's sample storage room in Punjab plant, says FDA report

  US health regulator Food and Drug Administration has found as many as eight lapses in Ranbaxy's Toansa plant in Punjab which was recently banned by the US drug inspectors from making products for the American market.

• US FDA bans more products from Ranbaxy

  The U.S. Food and Drug Administration said on Thursday it has banned more products from Indian drugmaker Ranbaxy Laboratories Ltd from entering the United States due to manufacturing violations.

• Suspected hair in tablet cited in Ranbaxy import alert

  During a visit to a facility of leading drugmaker Ranbaxy Laboratories Ltd last year, US inspectors found that a black fibre embedded in a tablet may have been a hair from an employee's arm, according to documents seen by Reuters.

• India says its drugs safe despite Ranbaxy generics fraud

  India, known as the "pharmacy to the world", today defended its lucrative generic drug industry as safe and strongly regulated after the nation's biggest drug firm pleaded guilty to US charges of making adulterated medicines.

• Ranbaxy to pay $500 million in US lawsuit settlement

  Generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.

• Ranbaxy Laboratories recalls generic Lipitor in United States

  Drugmaker Ranbaxy Laboratories Ltd has recalled its generic version of Pfizer Inc's cholesterol-lowering drug Lipitor in the United States after certain batches were found to contain glass particles.